Impaired phosphate and tension homologue deleted on chromosome 10 expression and its prognostic role in radical surgery for hepatocellular carcinoma with family aggregation resulting from hepatitis B and liver cirrhosis

Experimental Biology and Medicine

Volumn 238, Issue 8, 2013, Pages 866-873

  Zhong, Yuesi ^a   Yan, Jian ^a   Deng, Meihai ^a   Hu, Kunpeng ^a   Yao, Zhicheng ^b   Zou, Yong ^a   Xu, Ruiyun ^a  

^a THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

hepatocellular carcinoma with family aggregation; liver cirrhosis; phosphate and tension homologue deleted on chromosome 10; prognosis

Indexed keywords

HEPATOCELLULAR CARCINOMA WITH FAMILY AGGREGATION; LIVER CIRRHOSIS; PHOSPHATE AND TENSION HOMOLOGUE DELETED ON CHROMOSOME 10; PROGNOSIS;

ADULT; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPATECTOMY; HEPATITIS B; HUMANS; INCIDENCE; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PTEN PHOSPHOHYDROLASE; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84883812390     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.1177/1535370213494654     Document Type: Article

References (32)

1. Chen JG,Zhang SW.Liver cancer epidemic in China: past present and future.Semin Cancer Biol. 2011;2:59-69.
2. Yu MW,Chang HC,Chen PJ,Liu CJ,Liaw YF,Lin SM,Lee SD,Lin SC,Lin CL,Chen CJ.Increased risk for hepatitis B-related liver cirrhosis in relatives of patients with hepatocellular carcinoma in northern Taiwan.Int J Epidemiol. 2002;31:1008-15.
3. Gao Y,Jiang Q,Zhou X,Ding B,Wang R,Zhao G,Chen Y.HBV infection and familial aggregation of liver cancer: an analysis of case-control family study.Cancer Causes Control. 2004;15:845-50.
4. Song P,Tang W,Tamura S,Hasegawa K,Sugawara Y,Dong J,Kokudo N.The management of hepatocellular carcinoma in Asia: a guideline combining quantitative and qualitative evaluation.BioScience Trends. 2010;4:283-7.
5. Gao JJ,Inagaki Y,Xue X,Qu XJ,Tang W.c-Met: a potential therapeutic target for hepatocellular carcinoma.Drug Discov Ther. 2011;5:2-11.
6. Gao J,Feng X,Inagaki Y,Song P,Kokudo N,Hasegawa K,Sugawara Y,Tang W.Des-γ-carboxy prothrombin and c-Met were concurrently and extensively expressed in hepatocellular carcinoma and associated with tumor recurrence.BioScience Trends. 2012;6:153-9.
7. Tang ZY.Hepatocellular carcinoma surgery: review of the past and prospects for the 21st century.J Surg Oncol. 2005;91:95-6.
8. Cully M,You H,Levine AJ,Mak TW.Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis.Nat Rev Cancer. 2006;6:184-92.
9. Vaish V,Sanyal SN.Role of Sulindac and Celecoxib in the regulation of angiogenesis during the early neoplasm of colon: exploring PI3-K/PTEN/Akt pathway to the canonical Wnt/β-catenin signaling.Biomed Pharmacother. 2012;2:169-76.
10. Tzenaki N,Andreou M,Stratigi K,Vergetaki A,Makrigiannakis A,Vanhaesebroeck B,Papakonstanti EA.High levels of p110δ PI3K expression in solid tumor cells suppress PTEN activity, generating cellular sensitivity to p110δ inhibitors through PTEN activation.FASEB J. 2012;3:156-64.
11. Meric-Bernstam F,Akcakanat A,Chen H,Do KA,Sangai T,Adkins F,Gonzalez-Angulo AM,Rashid A,Crosby K,Dong M,Phan AT,Wolff RA,Gupta S,Mills GB,Yao J.PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors.Clin Cancer Res. 2012;18:1777-89.
12. Ma DZ,Xu Z,Liang YL,Su JM,Li ZX,Zhang W,Wang LY,Zha XL.Down-regulation of PTEN expression due to loss of promoter activity in human hepatocellular carcinoma cell lines.World J Gastroenterol. 2005;11:4472-7.
13. Wan XW,Jiang M,Cao HF,He YQ,Liu SQ,Qiu XH,Wu MC,Wang HY.The alteration of PTEN tumor suppressor expression and its association with the histopathological features of human primary hepatocellular carcinoma.J Cancer Res Clin Oncol. 2003;129:100-6.
14. Zhou L,Rui JA,Ye DX,Wang SB,Chen SG,Qu Q.Edmondson-Steiner grading increases the predictive efficiency of TNM staging for long-term survival of patients with hepatocellular carcinoma after curative resection.World J Surg. 2008;32:1748-56.
15. Nishi H,Inoue Y,Kageshita T,Takata M,Ihn H.The expression of human high molecular weight melanoma-associated antigen in acral lentiginous melanoma.BioScience Trends. 2010;4:86-9.
16. Midorikawa Y,Tang W,Sugiyama Y.High-resolution mapping of copy number aberrations and identification of target genes in hepatocellular carcinoma.BioScience Trends. 2007;1:26-32.
17. Steelman LS,Bertrand FE,McCubrey JA.The complexity of PTEN: mutation, marker and potential target for therapeutic intervention.Expert Opin Ther Targets. 2004;8:537-50.
18. Nakamura N,Ramaswamy S,Vazquez F,Signoretti S,Loda M,Sellers WR.Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN.Mol Cell Biol. 2000;20:8969-82.
19. Guo L,Chen L,Bi S,Chai L,Wang Z,Cao C,Tao L,Li S.PTEN inhibits proliferation and functions of hypertrophic scar fibroblasts.Mol Cell Biochem. 2012;361:161-8.
20. WU RC,Li X,Schonthal AH.Transcriptional activation of p21WAF1 by PT EN/MMAC1 tumor suppressor.Mol Cell Biochem. 2000;203:59-71.
21. Diehl JA,Cheng M,Roussel MF,Sherr CJ.Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization.Genes Dev. 1998;12:3499-511.
22. Chen H,Shen X,Guo C,Zhu H,Zhou L,Zhu Y,Wang H,Zheng Y,Huang L.Phosphatase and tensin homolog reconstruction and vascular endothelial growth factor knockdown synergistically inhibit the growth of glioblastoma.Cancer Biother Radiopharm. 2010;25:713-21.
23. Dasari VR,Kaur K,Velpula KK,Gujrati M,Fassett D,Klopfenstein JD,Dinh DH,Rao JS.Upregulation of PTEN in glioma cells by cord blood mesenchymal stem cells inhibits migration via downregulation of the PI3K/Akt pathway.PLoS One. 2010;5:e10350-e10350.
24. Reid AH,Attard G,Brewer D,Miranda S,Riisnaes R,Clark J,Hylands L,Merson S,Vergis R,Jameson C,Høyer S,Sørenson KD,Borre M,Jones C,de Bono JS,Cooper CS.Novel, gross chromosomal alterations involving PTEN cooperate with allelic loss in prostate cancer.Mod Pathol. 2012;3:112-30.
25. Hu TH,Huang CC,Lin PR,Chang HW,Ger LP,Lin YW,Changchien CS,Lee CM,Tai MH.Expression and prognostic role of tumor suppressor gene PTEN/MMAC1/TEP1 in hepatocellular carcinoma.Cancer. 2003;97:1929-40.
26. Lu D,Qian J,Yin X,Xiao Q,Wang C,Zeng Y.Expression of PTEN and survivin in cervical cancer: promising biological markers for early diagnosis and prognostic evaluation.Br J Biomed Sci. 2012;69:143-6.
27. Foo WC,Rashid A,Wang H,Katz MH,Lee JE,Pisters PW,Wolff RA,Abbruzzese JL,Fleming JB,Wang H.Loss of phosphatase and tensin homolog expression is associated with recurrence and poor prognosis in patients with pancreatic ductal adenocarcinoma.Hum Pathol.
28. Ach T, Zeitler K, Schwarz-Furlan S, Baader K, Agaimy A, Rohrmeier C, Zenk J, Gosau M, Reichert TE, Brockhoff G, Ettl T. Aberrations of MET are associated with copy number gain of EGFR and loss of PTEN and predict poor outcome in patients with salivary gland cancer. Virchows Arch. Epub ahead of print 15 December 2012. DOI: 10.1007/s00428-012-1358-0.
29. Lotan TL,Gumuskaya B,Rahimi H,Hicks JL,Iwata T,Robinson BD,Epstein JI,De Marzo AM.Cytoplasmic PTEN protein loss distinguishes intraductal carcinoma of the prostate from high-grade prostatic intraepithelial neoplasia.Mod Pathol.
30. Jin C,Wang AJ,Liu X,Wang G.Relationship between expression and prognostic ability of PTEN, STAT3 and VEGF-C in colorectal cancer.Exp Ther Med. 2012;4:633-9.
31. Agarwal V,Campbell A,Beaumont KL,Cawkwell L,Lind MJ.PTEN protein expression in malignant pleural mesothelioma.Tumour Biol.
32. Kang-Park S,Im JH,Lee JH,Lee YI.PTEN modulates hepatitis B virus-X protein induced survival signaling in change liver cells.Virus Res. 2006;122:53-60.